'Three-Person IVF' Technique Moves Closer
By BBC,
BBC News
| 01. 19. 2012
It replaces defective genetic material in the egg in order to eliminate rare mitochondrial diseases.
After the consultation into "three-person IVF", ministers will decide whether to allow it in patients.
A £5.8m centre at Newcastle University, funded by the Wellcome Trust, will investigate the technique's safety.
Inherited defects
Mitochondria can be found within almost every human cell, and provide the energy they need to function.
Like the nucleus of the cell, they contain DNA, although in tiny quantities.
Approximately 1 in 5,000 babies is born with inherited defects in their mitochondrial DNA, the effects of which can be very severe, or even fatal, depending on which cells are affected.
Scientists believe they have found a way to substitute the defective mitochondria and hopefully prevent the child from developing a disease.
They take two eggs, one from the mother and another from a donor.
The nucleus of the donor egg is removed, leaving the rest of the egg contents, including the mitochondria, and is replaced with the nucleus from the mother's egg.
The resulting embryo has properly functioning mitochondria from the...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...